EVLO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
EVLO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Evelo Biosciences's enterprise value is $17.51 Mil. Evelo Biosciences's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 was $-74.40 Mil. Therefore, Evelo Biosciences's EV-to-EBITDA for today is -0.24.
The historical rank and industry rank for Evelo Biosciences's EV-to-EBITDA or its related term are showing as below:
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-05-06), Evelo Biosciences's stock price is $0.0435. Evelo Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $-14.000. Therefore, Evelo Biosciences's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
The historical data trend for Evelo Biosciences's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Evelo Biosciences Annual Data | ||||||||||||||||
Trend | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||
EV-to-EBITDA | Get a 7-Day Free Trial | -4.96 | -0.86 | -6.14 | -2.70 | -1.70 |
Evelo Biosciences Quarterly Data | ||||||||||||||||||||
Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | |
EV-to-EBITDA | Get a 7-Day Free Trial | -1.88 | -1.70 | -0.42 | -0.66 | -1.22 |
For the Biotechnology subindustry, Evelo Biosciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Evelo Biosciences's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Evelo Biosciences's EV-to-EBITDA falls into.
Evelo Biosciences's EV-to-EBITDA for today is calculated as:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA (TTM) |
= | 17.512 | / | -74.404 | |
= | -0.24 |
Evelo Biosciences's current Enterprise Value is $17.51 Mil.
Evelo Biosciences's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-74.40 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Evelo Biosciences (OTCPK:EVLO) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Evelo Biosciences's PE Ratio for today is calculated as:
PE Ratio | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 0.0435 | / | -14.000 | |
= | At Loss |
Evelo Biosciences's share price for today is $0.0435.
Evelo Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-14.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Please read Which price ratio outperforms the enterprise multiple?
Thank you for viewing the detailed overview of Evelo Biosciences's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Simba Gill | director, officer: President & CEO | 515 GALVESTON DR, REDWOOD CITY CA 94063 |
Mark Bodmer | officer: See Remarks | C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, SUITE 200, CAMBRIDGE MA 02139 |
Marella Thorell | officer: Chief Financial Officer | 1226 CHARTER LANE, AMBLER PA 19002 |
Duncan Mchale | officer: Chief Medical Officer | C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, SUITE 200, CAMBRIDGE MA 02139 |
Alexander C Reynolds | director | C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, SUITE 200, CAMBRIDGE MA 02139 |
Horizon Technology Finance Corp | 10 percent owner | 312 FARMINGTON AVENUE, FARMINGTON CT 06032 |
Jeffrey R. Moore | director | C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, SUITE 200, CAMBRIDGE MA 02139 |
Flagship Ventures Fund Iv, L.p. | 10 percent owner | 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142 |
Robert L. Rosiello | director | 400 SOMERSET CORPORATE BOULEVARD, BRIDGEWATER NJ 08807 |
Stephen J Carriere | officer: Principal Accounting Officer | |
David R Epstein | director | INTERNATIONAL FLAVORS & FRAGRANCES INC., 521 W. 57TH STREET, NEW YORK NY 10019 |
Lord Ara Darzi | director | C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, SUITE 200, CAMBRIDGE MA 02139 |
Flagship Pioneering Fund Vii, L.p. | 10 percent owner | 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142 |
Flagship Pioneering Fund Vii General Partner Llc | 10 percent owner | 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142 |
Tonya Williams | director | C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, SUITE 200, CAMBRIDGE MA 02139 |
From GuruFocus
By GuruFocusNews GuruFocusNews • 07-01-2022
By PRNewswire PRNewswire • 07-12-2022
By sperokesalga sperokesalga • 02-27-2023
By Ds*** Ds*** • 09-01-2022
By PRNewswire PRNewswire • 11-07-2022
By Value_Insider Value_Insider • 12-16-2022
By PurpleRose PurpleRose • 07-11-2022
By GuruFocusNews GuruFocusNews • 07-04-2022
By PurpleRose PurpleRose • 08-11-2022
By Marketwired • 10-17-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.